SCHEMBL21774352

SCHEMBL21774352

Cc1cc(OCNC(=O)C2CCCC2)n(-c2ccccc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 5/20 0.46
NPSR1 Q6W5P4 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2C9 P11712 1/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
EPHX2 P34913 1/20 0.44
RAB9A P51151 1/20 0.44
NTRK1 P04629 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21774320 0.99 KDM4E (0.47) KDM4EALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL21774368 0.95 ALDH1A1 (0.46) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL30076265 0.85 HSD17B10 (0.48) KDM4EALDH1A1MAPTHTTL3MBTL1
SCHEMBL30076243 0.84 HSD17B10 (0.48) KDM4EALDH1A1MAPTHTTL3MBTL1
SCHEMBL30076376 0.82 ALDH1A1 (0.47) KDM4EALDH1A1NPSR1CYP1A2CYP2C19
SCHEMBL21774134 0.82 NTRK1 (0.50) ALDH1A1LMNAGAAMAPTHTT
SCHEMBL21775687 0.82 ALDH1A1 (0.45) ALDH1A1LMNAGAAMAPTL3MBTL1
SCHEMBL25763340 0.81 ALDH1A1 (0.44) ALDH1A1NPSR1LMNAGAAMAPT
SCHEMBL21774357 0.80 ALDH1A1 (0.51) KDM4EALDH1A1NPSR1CYP1A2CYP2C19
SCHEMBL21753650 0.80 GAA (0.57) ALDH1A1CYP1A2CYP2C19CYP2C9GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 US disclosed
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 US disclosed
WO-2020038279-A1 SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 天津谷堆生物医药科技有限公司 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof FARS2, GOT2, HADHB KDM4E 4279/4885ALDH1A1 2197/4885NPSR1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.